{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:10:12Z","timestamp":1786990212755,"version":"build-2736575974"},"reference-count":55,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.hoc.2019.04.004","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T09:26:10Z","timestamp":1558603570000},"page":"669-686","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Overview of Cutaneous T-Cell Lymphomas"],"prefix":"10.1016","volume":"33","author":[{"given":"Cecilia A.","family":"Larocca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole R.","family":"LeBoeuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.hoc.2019.04.004_bib1","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","article-title":"Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases","volume":"113","author":"Bradford","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2019.04.004_bib2","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jamadermatol.2013.5526","article-title":"Changing incidence trends of cutaneous T-cell lymphoma","volume":"149","author":"Korgavkar","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"10","key":"10.1016\/j.hoc.2019.04.004_bib3","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2019.04.004_bib4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/PAP.0000000000000208","article-title":"Cutaneous lymphoproliferative disorders: what's new in the revised 4th edition of the World Health Organization (WHO) classification of lymphoid neoplasms","volume":"26","author":"Sundram","year":"2018","journal-title":"Adv Anat Pathol"},{"issue":"6","key":"10.1016\/j.hoc.2019.04.004_bib5","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"issue":"308","key":"10.1016\/j.hoc.2019.04.004_bib6","doi-asserted-by":"crossref","first-page":"308ra158","DOI":"10.1126\/scitranslmed.aaa9122","article-title":"TCR sequencing facilitates diagnosis and identifies mature T\u00a0cells as the cell of origin in CTCL","volume":"7","author":"Kirsch","year":"2015","journal-title":"Sci Transl Med"},{"issue":"279","key":"10.1016\/j.hoc.2019.04.004_bib7","doi-asserted-by":"crossref","first-page":"279ra239","DOI":"10.1126\/scitranslmed.3010302","article-title":"Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T\u00a0cells","volume":"7","author":"Watanabe","year":"2015","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.hoc.2019.04.004_bib8","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2009-11-251926","article-title":"Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors","volume":"116","author":"Campbell","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2019.04.004_bib9","article-title":"The PROCLIPI international registry of early stage Mycosis Fungoides identifies substantial diagnostic delay in most patients","author":"Scarisbrick","year":"2018","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.hoc.2019.04.004_bib10","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1034\/j.1600-0560.2001.028004174.x","article-title":"Histologic criteria for the diagnosis of mycosis fungoides: proposal for a grading system to standardize pathology reporting","volume":"28","author":"Guitart","year":"2001","journal-title":"J\u00a0Cutan Pathol"},{"issue":"6","key":"10.1016\/j.hoc.2019.04.004_bib11","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jaad.2005.08.057","article-title":"Defining early mycosis fungoides","volume":"53","author":"Pimpinelli","year":"2005","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"440","key":"10.1016\/j.hoc.2019.04.004_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar5894","article-title":"High-throughput sequencing of the T\u00a0cell receptor beta gene identifies aggressive early-stage mycosis fungoides","volume":"10","author":"de Masson","year":"2018","journal-title":"Sci Transl Med"},{"issue":"9","key":"10.1016\/j.hoc.2019.04.004_bib13","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1001\/jamadermatol.2016.1597","article-title":"Clinical staging and prognostic factors in folliculotropic mycosis fungoides","volume":"152","author":"van Santen","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"12","key":"10.1016\/j.hoc.2019.04.004_bib14","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/DAD.0000000000000207","article-title":"Mycosis fungoides: an updated review of clinicopathologic variants","volume":"36","author":"Ahn","year":"2014","journal-title":"Am J Dermatopathol"},{"issue":"4","key":"10.1016\/j.hoc.2019.04.004_bib15","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.mpdhp.2016.04.004","article-title":"Unusual variants of mycosis fungoides","volume":"22","author":"Virmani","year":"2016","journal-title":"Diagn Histopathol (Oxf)"},{"issue":"5","key":"10.1016\/j.hoc.2019.04.004_bib16","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/archderm.142.5.577","article-title":"Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography","volume":"142","author":"Tsai","year":"2006","journal-title":"Arch Dermatol"},{"issue":"31","key":"10.1016\/j.hoc.2019.04.004_bib17","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2019.04.004_bib18","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.hoc.2019.04.004_bib19","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/bjd.12909","article-title":"Prognostic factors, prognostic indices and staging in mycosis fungoides and Sezary syndrome: where are we now?","volume":"170","author":"Scarisbrick","year":"2014","journal-title":"Br J Dermatol"},{"issue":"32","key":"10.1016\/j.hoc.2019.04.004_bib20","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and sezary syndrome: effect of specific prognostic markers on survival and development of a prognostic model","volume":"33","author":"Scarisbrick","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2019.04.004_bib21","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/ajh.24876","article-title":"Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management","volume":"92","author":"Wilcox","year":"2017","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.hoc.2019.04.004_bib22","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.bbmt.2017.07.027","volume":"23","author":"Kharfan-Dabaja","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.hoc.2019.04.004_bib23","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1182\/blood-2017-02-768234","article-title":"Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E)","volume":"130","author":"Park","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2019.04.004_bib24","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/mgg3.121","article-title":"Personalized treatment of Sezary syndrome by targeting a novel CTLA4:CD28 fusion","volume":"3","author":"Sekulic","year":"2015","journal-title":"Mol Genet Genomic Med"},{"issue":"15","key":"10.1016\/j.hoc.2019.04.004_bib25","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2011-05-351346","article-title":"EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma","volume":"118","author":"Kempf","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2019.04.004_bib26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1053\/j.semdp.2016.11.005","article-title":"A\u00a0new era for cutaneous CD30-positive T-cell lymphoproliferative disorders","volume":"34","author":"Kempf","year":"2017","journal-title":"Semin Diagn Pathol"},{"issue":"6","key":"10.1016\/j.hoc.2019.04.004_bib27","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0190-9622(03)02484-8","article-title":"CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma","volume":"49","author":"Liu","year":"2003","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.hoc.2019.04.004_bib28","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.hoc.2016.11.006","article-title":"CD30(+) lymphoproliferative disorders of the skin","volume":"31","author":"Sauder","year":"2017","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"10.1016\/j.hoc.2019.04.004_bib29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaad.2015.09.013","article-title":"Lymphomatoid papulosis: treatment response and associated lymphomas in a study of 180 patients","volume":"74","author":"Wieser","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.hoc.2019.04.004_bib30","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1182\/blood.V95.12.3653","article-title":"Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment","volume":"95","author":"Bekkenk","year":"2000","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2019.04.004_bib31","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/j.1600-0560.2006.00560.x","article-title":"Detection of clonal rearrangement of T-cell receptor genes in the diagnosis of primary cutaneous CD30 lymphoproliferative disorders","volume":"33","author":"Greisser","year":"2006","journal-title":"J\u00a0Cutan Pathol"},{"issue":"2","key":"10.1016\/j.hoc.2019.04.004_bib32","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood-2007-04-087288","article-title":"Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases","volume":"111","author":"Willemze","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2019.04.004_bib33","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1097\/PAS.0b013e31826a5038","article-title":"Cutaneous gammadelta T-cell lymphomas: a spectrum of presentations with overlap with other cytotoxic lymphomas","volume":"36","author":"Guitart","year":"2012","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"10.1016\/j.hoc.2019.04.004_bib34","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/ng.3442","article-title":"The mutational landscape of cutaneous T\u00a0cell lymphoma and Sezary syndrome","volume":"47","author":"da Silva Almeida","year":"2015","journal-title":"Nat Genet"},{"issue":"12","key":"10.1016\/j.hoc.2019.04.004_bib35","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1001\/jamadermatol.2016.3117","article-title":"Cutaneous gamma-delta T-cell lymphoma successfully treated with brentuximab vedotin","volume":"152","author":"Rubio-Gonzalez","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.hoc.2019.04.004_bib36","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jaad.2015.01.003","article-title":"Hematopoietic stem cell transplantation for primary cutaneous gammadelta T-cell lymphoma and refractory subcutaneous panniculitis-like T-cell lymphoma","volume":"72","author":"Gibson","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.hoc.2019.04.004_bib37","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/PAS.0000000000000768","article-title":"Primary cutaneous T-Cell lymphomas showing gamma-delta (gammadelta) phenotype and predominantly epidermotropic pattern are clinicopathologically distinct from classic primary cutaneous gammadelta T-cell lymphomas","volume":"41","author":"Merrill","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1016\/j.hoc.2019.04.004_bib38","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jaad.2016.06.011","article-title":"Cutaneous peripheral T-cell lymphoma, not otherwise specified: a single-center prognostic analysis","volume":"75","author":"Tolkachjov","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.hoc.2019.04.004_bib39","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0002-9440(10)65144-9","article-title":"Primary cutaneous CD8-positive epidermotropic cytotoxic T\u00a0cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior","volume":"155","author":"Berti","year":"1999","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.hoc.2019.04.004_bib40","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jaad.2009.02.035","article-title":"Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma","volume":"62","author":"Gormley","year":"2010","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.hoc.2019.04.004_bib41","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/bjd.13765","article-title":"Indolent CD8-positive lymphoid proliferation of acral sites: identifying the sheep in wolf's clothing","volume":"172","author":"Goodlad","year":"2015","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.hoc.2019.04.004_bib42","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/cup.12633","article-title":"Indolent CD8-positive lymphoid proliferation of acral sites: three further cases of a rare entity and an update on a unique patient","volume":"43","author":"Kluk","year":"2016","journal-title":"J\u00a0Cutan Pathol"},{"issue":"11","key":"10.1016\/j.hoc.2019.04.004_bib43","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/ijd.13340","article-title":"Long-term follow-up and management of small and medium-sized CD4(+) T\u00a0cell lymphoma and CD8(+) lymphoid proliferations of acral sites: a multicenter experience","volume":"55","author":"Virmani","year":"2016","journal-title":"Int J Dermatol"},{"issue":"2","key":"10.1016\/j.hoc.2019.04.004_bib44","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/cup.12045","article-title":"Indolent CD8(+) lymphoid proliferation of acral sites: a clinicopathologic study of six patients with some atypical features","volume":"40","author":"Greenblatt","year":"2013","journal-title":"J\u00a0Cutan Pathol"},{"issue":"11","key":"10.1016\/j.hoc.2019.04.004_bib45","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.5858\/arpa.2017-0230-RA","article-title":"Primary cutaneous acral CD8(+) T-cell lymphoma","volume":"141","author":"Hathuc","year":"2017","journal-title":"Arch Pathol Lab Med"},{"issue":"4","key":"10.1016\/j.hoc.2019.04.004_bib46","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3109\/10428194.2014.938331","article-title":"CD4\u00a0+ primary cutaneous small\/medium-sized pleomorphic T-cell lymphoma: a retrospective case series and review of literature","volume":"56","author":"James","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"18","key":"10.1016\/j.hoc.2019.04.004_bib47","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1182\/blood-2018-03-785972","article-title":"How I treat breast implant-associated anaplastic large cell lymphoma","volume":"132","author":"Mehta-Shah","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2019.04.004_bib48","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/asj\/sjw259","article-title":"NCCN consensus guidelines for the diagnosis and management of breast implant-associated anaplastic large cell lymphoma","volume":"37","author":"Clemens","year":"2017","journal-title":"Aesthet Surg J"},{"issue":"9","key":"10.1016\/j.hoc.2019.04.004_bib49","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1080\/17474086.2016.1206465","article-title":"Diagnosis and management of extranodal NK\/T cell lymphoma nasal type","volume":"9","author":"Tse","year":"2016","journal-title":"Expert Rev Hematol"},{"issue":"25","key":"10.1016\/j.hoc.2019.04.004_bib50","doi-asserted-by":"crossref","first-page":"4997","DOI":"10.1182\/blood-2013-01-453233","article-title":"How I treat NK\/T-cell lymphomas","volume":"121","author":"Tse","year":"2013","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2019.04.004_bib51","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.clml.2018.04.009","article-title":"Natural killer\/T-cell neoplasms: analysis of incidence, patient characteristics, and survival outcomes in the United States","volume":"18","author":"Kommalapati","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.hoc.2019.04.004_bib52","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11899-014-0216-3","article-title":"Management of advanced NK\/T-cell lymphoma","volume":"9","author":"Tse","year":"2014","journal-title":"Curr Hematol Malig Rep"},{"issue":"17","key":"10.1016\/j.hoc.2019.04.004_bib53","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.hoc.2019.04.004_bib54","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1182\/blood-2013-05-502203","article-title":"Hydroa vacciniforme-like lymphoma: a chronic EBV+ lymphoproliferative disorder with risk to develop a systemic lymphoma","volume":"122","author":"Quintanilla-Martinez","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2019.04.004_bib55","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/DAD.0000000000001229","article-title":"Comparative study of the clinical pathology, immunophenotype, epstein-barr virus infection status, and gene rearrangements in adult and children patients with hydroa vacciniforme-like lymphoproliferative disorder","volume":"41","author":"Wen","year":"2019","journal-title":"Am J Dermatopathol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858819300553?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858819300553?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:12:15Z","timestamp":1760184735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858819300553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0889858819300553"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2019.04.004","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overview of Cutaneous T-Cell Lymphomas","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2019.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}